Timothy Devos

3.3k total citations
91 papers, 1.3k citations indexed

About

Timothy Devos is a scholar working on Genetics, Hematology and Immunology. According to data from OpenAlex, Timothy Devos has authored 91 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Genetics, 46 papers in Hematology and 17 papers in Immunology. Recurrent topics in Timothy Devos's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (46 papers), Chronic Myeloid Leukemia Treatments (27 papers) and Eosinophilic Disorders and Syndromes (13 papers). Timothy Devos is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (46 papers), Chronic Myeloid Leukemia Treatments (27 papers) and Eosinophilic Disorders and Syndromes (13 papers). Timothy Devos collaborates with scholars based in Belgium, United States and France. Timothy Devos's co-authors include Miklós Egyed, Ruben A. Mesa, Jean‐Jacques Kiladjian, Francesco Passamonti, Alessandro M. Vannucchi, Daan Dierickx, Donal P. McLornan, John Catalano, Jeannie Callum and Francesca Palandri and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Timothy Devos

83 papers receiving 1.3k citations

Peers

Countries citing papers authored by Timothy Devos

Since Specialization

Citations

This map shows the geographic impact of Timothy Devos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Devos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Devos more than expected).

Fields of papers citing papers by Timothy Devos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Devos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Devos. The network helps show where Timothy Devos may publish in the future.

Co-authorship network of co-authors of Timothy Devos

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Devos. A scholar is included among the top collaborators of Timothy Devos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Devos. Timothy Devos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neutrophils as critical orchestrators of chronic inflammation 2026 ·Cellular and Molecular Immunology ·(unknown), (unknown), (unknown), Timothy Devos, (unknown), (unknown)	0
2	POSTER: MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Vikas Gupta, Stephen T. Oh, Timothy Devos, Viviane Dubruille, John Catalano, (unknown), Pilar Giraldo, Hiroshi Kosugi, Tomasz Sacha, Jiří Mayer, Árpád Illés, Catherine Ellis, Zhaohui Wang, Jun Kawashima, Ruben A. Mesa	1
3	Characterization of the Human Blood Virome in Iranian Multiple Transfused Patients 2023 ·Viruses ·Marijn Thijssen, Gholamreza Khamisipour, (unknown), Timothy Devos, Guangdi Li, Marc Van Ranst, Jelle Matthijnssens, Mahmoud Reza Pourkarim	2
4	Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry 2023 ·Annals of Hematology ·Britta Höchsmann, Régis Peffault de Latour, A. Bradford Hill, Alexander Röth, Timothy Devos, Christopher J. Patriquin, Wen‐Chien Chou, Deepak Jain, Ke Zu, Chuntao Wu, Jong Wook Lee	9
5	Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study 2023 ·European Journal Of Haematology ·(unknown), Heinz Gisslinger, Valerio De Stefano, Vincenzo Accurso, Alessandra Iurlo, Timothy Devos, Miklós Egyed, Éric Lippert, (unknown), Nathan Cantoni, Anders Erik Astrup Dahm, Damianos Sotiropoulos, (unknown), (unknown), Amir Iqbal, P. Di Matteo, Mike W. Zuurman, Peter A.W. te Boekhorst	1
6	Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria 2023 ·Annals of Hematology ·Hubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell, Régis Peffault de Latour, Timothy Devos, Shinichiro Okamoto, Richard A. Wells, Evan Popoff, Antoinette Cheung, (unknown), Ioannis Tomazos, Yogesh Patel, Jong Wook Lee	6
7	Germline heterozygous SH2B3‐mutations and (idiopathic) erythrocytosis: Detection of a previously undescribed mutation 2023 ·SHILAP Revista de lepidopterología ·(unknown), Timothy Devos, (unknown), Frédéric Lambert, Bruce Poppe, (unknown)	1
8	Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis 2022 ·Leukemia ·Ruben A. Mesa, Claire Harrison, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean‐Jacques Kiladjian, Ewa Lech‐Marańda, Donal P. McLornan, Alessandro M. Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara Klencke, Srđan Verstovšek	40
9	Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis 2021 ·Hematology ·Timothy Devos, Dominik Selleslag, (unknown), Violaine Havelange, Fleur Samantha Benghiat	10
10	Recanalization of portal axis after cavoportal hemitransposition in a liver transplant recipient with complete splanchnic thrombosis 2021 ·Pediatric Transplantation ·(unknown), Alexander Wilmer, Yves Debaveye, Wim Laleman, Timothy Devos, (unknown), Chris Verslype, Van der Merwe, Hannah van Malenstein, Frederik Nevens, Geert Maleux, Mauricio Sainz‐Barriga, Diethard Monbaliu, Jacques Pirenne	0
11	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases 2020 ·Microorganisms ·Marijn Thijssen, Timothy Devos, (unknown), Samad Amini‐Bavil‐Olyaee, Ali Akbar Pourfathollah, Mahmoud Reza Pourkarim	14
12	Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel 2018 ·European Journal Of Haematology ·Timothy Devos, Stef Meers, Nancy Boeckx, André Gothot, Dries Deeren, Bernard Châtelain, C Chatelain, Bérangère Devalet	31
13	Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients 2018 ·Hematology ·(unknown), Lucienne Michaux, Koen Debackere, Els Lierman, Peter Vandenberghe, Timothy Devos	14
14	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis 2017 ·Journal of Clinical Oncology ·Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, (unknown), Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib	238
15	Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey 2017 ·European Journal Of Haematology ·Timothy Devos, Yves Béguin, Lucien Noens, Koen Van Eygen, Pierre Zachée, Philippe Mineur, Laurent Knoops, Chantal Doyen, Koen Theunissen, Fleur Samantha Benghiat, (unknown), (unknown)	4
16	Real-world data from 54 Belgian patients from the ponatinib named patient programme (NPP) 2016 ·Ghent University Academic Bibliography (Ghent University) ·L. Knoops, Gregor Verhoef, Z. N. Berneman, (unknown), Nicole Straetmans, Lucien Noens, Pierre Lewalle, (unknown), (unknown), Pierre Zachée, (unknown), Lisa J. McGarry, Timothy Devos	1
17	Prospective Evaluation of WHO and European Clinical, Molecular and Pathological (WHO-ECMP) Criteria for Myeloproliferative Neoplasms (MPN) of Various Molecular Etiology: Characteristics of JAK2V617F, MPL515 and CALR Mutated MPN 2015 ·Michiels Jj, Timothy Devos, Karel Fostier, (unknown), (unknown), Katrien Schelfout, (unknown)	0
18	Characteristics, treatment and prognosis of primary central nervous system lymphoma: a single center retrospective study 2014 ·Acta Clinica Belgica ·Daan Dierickx, (unknown), (unknown), Gregor Verhoef, Paul M. Clément, Philippe Demaerel, Thomas Tousseyn, Michel Delforge, Timothy Devos, Ann Janssens, Johan Maertens, Hélène Schoemans	1
19	Myelofibrosis patients in Belgium: disease characteristics 2014 ·Acta Clinica Belgica ·Timothy Devos, Pierre Zachée, Dominique Bron, Lucien Noens, Jan Van Droogenbroeck, Philippe Mineur, Yves Béguin, Zwi Berneman, Fleur Samantha Benghiat, Alain Kentos, C Chatelain, H Demuynck, Jan Lemmens, Koen Van Eygen, Koen Theunissen, Fabienne Trullemans, P. Pierre, (unknown), L. Knoops	6
20	Natural Killer cells are required for rapidly induced xeno-antibody production by Marginal Zone B cells 2005 ·Xenotransplantation ·Timothy Devos, Jozef Laureys, (unknown), Omer Rutgeerts, Conny Gysemans, (unknown), Yuan Lin, B. Van Damme, Chantal Mathieu	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact